

Ramiro Garzon

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11964887/ramiro-garzon-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

127
papers

17,883
citations

47
h-index

131
g-index

131
ext. papers

19,376
ext. citations

8.1
avg, IF

6.21
L-index

#	Paper	IF	Citations
127	Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60-75. <i>Blood</i> , 2021 , 138, 4125-4125	2.2	1
126	Epidermal Growth Factor-like 7 As a Novel Therapeutic Target in Mantle Cell Lymphoma. <i>Blood</i> , 2021 , 138, 3300-3300	2.2	
125	Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. <i>Blood Advances</i> , 2021 , 5, 1474-1482	7.8	4
124	Targeting BRD4 in acute myeloid leukemia with partial tandem duplication of the gene. <i>Haematologica</i> , 2021 , 106, 2527-2532	6.6	0
123	ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia. <i>Molecular Cell</i> , 2021 , 81, 2752-2764.e6	17.6	4
122	Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , 2021 ,	6.6	1
121	Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 107	22.4	2
120	Methods Used to Make Lipid Nanoparticles to Deliver LNA Gapmers Against lncRNAs into Acute Myeloid Leukemia (AML) Blasts. <i>Methods in Molecular Biology</i> , 2021 , 2348, 167-174	1.4	
119	DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. <i>Genome Research</i> , 2021 , 31, 747-761	9.7	4
118	Clinical Applications of MicroRNAs in Acute Myeloid Leukemia: A Mini-Review. <i>Frontiers in Oncology</i> , 2021 , 11, 679022	5.3	1
117	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on Antiproliferative and PP2A-Activating Functions. <i>Blood Cancer Discovery</i> , 2020 , 1, 48-67	7	16
116	Selinexor for advanced hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2335-2350	1.9	7
115	Phase I study of AR-42 and decitabine in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1484-1492	1.9	9
114	PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease. <i>JCI Insight</i> , 2020 , 5,	9.9	15
113	Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance). <i>Blood</i> , 2020 , 136, 20-21	2.2	2
112	EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2020 , 26, 669-678	12.9	8
111	A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2020 , 95, 1457-1465	7.1	1

110	Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. <i>Investigational New Drugs</i> , 2020 , 38, 340-349	4.3	13
109	Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. <i>Leukemia and Lymphoma</i> , 2020 , 61, 387-396	1.9	12
108	Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. <i>Haematologica</i> , 2020 , 105, 721-729	6.6	7
107	Clinical and functional significance of circular RNAs in cytogenetically normal AML. <i>Blood Advances</i> , 2020 , 4, 239-251	7.8	16
106	Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1451-1459	6.1	3
105	Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells. <i>Leukemia</i> , 2019 , 33, 2169-2182	10.7	33
104	Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD) 2019 , 2, 079-82		
103	The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia. <i>Nature Communications</i> , 2019 , 10, 5351	17.4	38
102	MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. <i>Journal of Immunology</i> , 2018 , 200, 4170-4179	5.3	15
101	A novel regimen for relapsed/refractory adult acute myeloid leukemia using a partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. <i>Haematologica</i> , 2018 , 103, 982-987	6.6	11
100	A 17-Gene Leukemia Stem Cell (LSC) Score in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Reveals a Distinct Mutational Landscape and Refines Current European Leukemianet (ELN) Genetic Risk Stratification. <i>Blood</i> , 2018 , 132, 289-289	2.2	2
99	Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. <i>Oncotarget</i> , 2018 , 9, 4354-4365	3.3	11
98	Prognostic and Biologic Significance of Long Non-Coding RNA (lncRNA) Profiling in Cytogenetically Abnormal Acute Myeloid Leukemia (CA-AML). <i>Blood</i> , 2018 , 132, 2767-2767	2.2	
97	Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2018 , 24, 608-618	12.9	10
96	Knockout of both miR-15/16 loci induces acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 13069-13074	11.5	26
95	Toll-Like Receptor Stimulation by MicroRNAs in Acute Graft-vs.-Host Disease. <i>Frontiers in Immunology</i> , 2018 , 9, 2561	8.4	5
94	Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. <i>Journal of Immunology</i> , 2017 , 198, 2500-2512	5.3	32
93	Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. <i>Blood</i> , 2017 , 129, 3175-3183	2.2	88

92	Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , 2017 , 102, 1391-1400	6.6	23
91	Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E4641-E4647	11.5	25
90	A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. <i>Blood</i> , 2017 , 129, 3165-3174	2.2	82
89	Long noncoding RNAs to predict survival in acute myeloid leukemia: a step toward personalized medicine?. <i>Biomarkers in Medicine</i> , 2016 , 10, 935-8	2.3	1
88	MiR-155 Impacts T Cell Migration in Acute Graft-Versus-Host-Disease (aGVHD). <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, S58-S59	4.7	
87	Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2016 , 6, 1036-51	24.4	8
86	Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2100-8	1.9	34
85	HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2016 , 22, 3537-49	12.9	45
84	Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 71-9	4.7	6
83	HOXB-AS3 Regulates Cell Cycle Progression and Interacts with the Drosophila Splicing Human Behavior (DSHB) Complex in NPM1-Mutated Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 1514-1514	2.2	4
82	Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 2831-2831	2.2	8
81	The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 3941-3941	2.2	3
80	MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. <i>Oncotarget</i> , 2016 , 7, 55395-55408	3.3	21
79	Potential Targeting Ph+ Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity. <i>Blood</i> , 2016 , 128, 2909-2909	2.2	1
78	EGFL7 Antagonizes NOTCH Signaling, Stimulates Blast Proliferation and Confers Poor Prognosis in Cytogenetically-Normal Acute Myeloid Leukemia (CN-AML). <i>Blood</i> , 2016 , 128, 2689-2689	2.2	
77	Acute Myeloid Leukemia: A Concise Review. <i>Journal of Clinical Medicine</i> , 2016 , 5,	5.1	161
76	XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase III α to the Nucleus. <i>Clinical Cancer Research</i> , 2016 , 22, 6142-6152	12.9	53
75	miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. <i>Blood</i> , 2016 , 128, 1424-35	2.2	46

74	Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. <i>Blood</i> , 2015 , 125, 2689-92	2.2	37
73	Clinical Implications of MicroRNAs in AML 2015 , 699-705		2
72	Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. <i>Journal of Clinical Oncology</i> , 2014 , 32, 548-56	2.2	119
71	The use of molecular genetics to refine prognosis in acute myeloid leukemia. <i>Current Hematologic Malignancy Reports</i> , 2014 , 9, 148-57	4.4	9
70	Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. <i>Blood</i> , 2014 , 123, 2412-5	2.2	40
69	A large scale expression study associates uc.283-plus lncRNA with pluripotent stem cells and human glioma. <i>Genome Medicine</i> , 2014 , 6, 76	14.4	29
68	Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1304-8	1.9	21
67	Expression and prognostic impact of lncRNAs in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 18679-84	11.5	181
66	Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	25
65	SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. <i>Journal of Clinical Investigation</i> , 2014 , 124, 1512-24	15.9	42
64	Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2013 , 6, 21	22.4	42
63	In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia. <i>AAPS Journal</i> , 2013 , 15, 242-9	3.7	14
62	Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults. <i>British Journal of Haematology</i> , 2013 , 161, 406-10	4.5	38
61	Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. <i>Blood</i> , 2013 , 122, 3034-44	2.2	114
60	Lenalidomide-mediated enhanced translation of C/EBP β 30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. <i>Blood</i> , 2013 , 121, 159-69	2.2	53
59	Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. <i>Clinical Cancer Research</i> , 2013 , 19, 2355-67	12.9	146
58	Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2086-93	2.2	141
57	CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2013 , 123, 2395-407	15.9	147

56 MicroRNAs and Hematopoiesis **2013**, 91-100

55	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. <i>Journal of Clinical Investigation</i> , 2013 , 123, 4144-57	15.9	170
54	Decitabine Priming Enhances The Antileukemic Effects Of The Selective Inhibitor Of Nuclear Export (SINE) CRM1/XPO1 Antagonist (Selinexor) In Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013 , 122, 1453-1453	2.2	2
53	Serum Mir-29a Is Up-Regulated In Acute Graft Versus Host Disease (aGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) and Activates Dendritic Cells (DCs). <i>Blood</i> , 2013 , 122, 4471-4471	2.2	1
52	Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Of a First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013 , 122, 90-90	2.2	19
51	A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2'ED-Methylphosphorothioate Mir-29b. <i>Blood</i> , 2013 , 122, 3933-3933	2.2	
50	Phase I Study Of The Combination Of Midostaurin, Bortezomib and Chemotherapy In Relapsed/Refractory Acute Myeloid Leukemia (AML): Targeting Aberrant Tyrosine Kinase Activity. <i>Blood</i> , 2013 , 122, 3966-3966	2.2	
49	Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 1765-73	2.2	161
48	Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 2466-74	2.2	64
47	Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. <i>Cancer Cell</i> , 2012 , 22, 645-55	24.3	115
46	Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity. <i>Molecular Pharmaceutics</i> , 2012 , 9, 1638-44	5.6	22
45	Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. <i>Blood</i> , 2012 , 119, 6025-31	2.2	119
44	Regulation of acute graft-versus-host disease by microRNA-155. <i>Blood</i> , 2012 , 119, 4786-97	2.2	108
43	Potential of microRNAs for cancer diagnostics, prognostication and therapy. <i>Current Opinion in Oncology</i> , 2012 , 24, 655-9	4.2	58
42	miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the EμmiR-155 transgenic mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 20047-52	11.5	103
41	Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results. <i>Blood</i> , 2012 , 120, 3616-3616	2.2	
40	Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. <i>Seminars in Oncology</i> , 2011 , 38, 781-7	5.5	38
39	The prognostic and functional role of microRNAs in acute myeloid leukemia. <i>Blood</i> , 2011 , 117, 1121-9	2.2	218

38	Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. <i>Cancer</i> , 2011 , 117, 4696-706	6.4	52
37	Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. <i>Hematological Oncology</i> , 2011 , 29, 202-10	1.3	12
36	Micro-RNA Expression and Function in Lymphomas. <i>Advances in Hematology</i> , 2011 , 2011, 347137	1.5	29
35	Targeting microRNAs in cancer: rationale, strategies and challenges. <i>Nature Reviews Drug Discovery</i> , 2010 , 9, 775-89	64.1	1143
34	Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5257-64	2.2	155
33	Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 7473-8	11.5	399
32	Dose escalation of lenalidomide in relapsed or refractory acute leukemias. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4919-25	2.2	73
31	miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. <i>Cell</i> , 2010 , 140, 652-65	56.2	427
30	A novel ultrasensitive hybridization-based ELISA method for 2-methoxyphosphorothiolate microRNAs and its in vitro and in vivo application. <i>AAPS Journal</i> , 2010 , 12, 556-68	3.7	14
29	Reprogramming of miRNA networks in cancer and leukemia. <i>Genome Research</i> , 2010 , 20, 589-99	9.7	287
28	Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. <i>Cancer Cell</i> , 2010 , 17, 333-47	24.3	218
27	MicroRNAs: emerging key regulators of hematopoiesis. <i>American Journal of Hematology</i> , 2010 , 85, 935-42	4.1	73
26	Regulation of Acute Graft-Versus-Host Disease by MicroRNA-155. <i>Blood</i> , 2010 , 116, 245-245	2.2	
25	Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. <i>Journal of Biological Chemistry</i> , 2009 , 284, 15676-84	5.4	450
24	MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. <i>Blood</i> , 2009 , 113, 6411-8	2.2	655
23	Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1422-30	4.7	79
22	MicroRNAs in Cancer. <i>Annual Review of Medicine</i> , 2009 , 60, 167-79	17.4	1516
21	MicroRNA 29b functions in acute myeloid leukemia. <i>Blood</i> , 2009 , 114, 5331-41	2.2	379

20	MicroRNA profiling of megakaryocytes. <i>Methods in Molecular Biology</i> , 2009 , 496, 293-8	1.4	
19	Evidence of MicroRNA-29b and Sp1/NFB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.. <i>Blood</i> , 2009 , 114, 938-938	2.2	0
18	NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. <i>Cancer Cell</i> , 2008 , 14, 369-81	24.3	496
17	MiR-15a and miR-16-1 cluster functions in human leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 5166-71	11.5	642
16	Implications of MicroRNAs in Normal Hematopoiesis and Human Leukemia. <i>Clinical Leukemia</i> , 2008 , 2, 96-101		
15	MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 12885-90	11.5	467
14	MicroRNA expression in cytogenetically normal acute myeloid leukemia. <i>New England Journal of Medicine</i> , 2008 , 358, 1919-28	59.2	386
13	Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3945-50	11.5	426
12	MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. <i>Blood</i> , 2008 , 111, 3183-9	2.2	536
11	Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. <i>Blood</i> , 2008 , 111, 2364-73	2.2	124
10	MicroRNAs in normal and malignant hematopoiesis. <i>Current Opinion in Hematology</i> , 2008 , 15, 352-8	3.3	197
9	MicroRNAs in the diagnosis, prognosis and treatment of cancer. <i>Oncology Reviews</i> , 2008 , 2, 203-213	4.3	3
8	A microRNA signature of hypoxia. <i>Molecular and Cellular Biology</i> , 2007 , 27, 1859-67	4.8	881
7	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 15805-10	11.5	1385
6	MiRNA-29b Targets MCL-1 and Is Down-Regulated in Chemotherapy-Resistant Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007 , 110, 717-717	2.2	2
5	MicroRNA fingerprints during human megakaryocytopoiesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 5078-83	11.5	386
4	MicroRNA expression and function in cancer. <i>Trends in Molecular Medicine</i> , 2006 , 12, 580-7	11.5	615
3	A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2005 , 353, 1793-801	59.2	2041

2 Acute bulbar muscle dysfunction in hyperthyroidism. *Connecticut Medicine*, **2002**, 66, 3-6

1

1 High throughput microRNAs profiling in cancers309-321